 |
|
|
| |
Treatment With SOF/VEL or SOF/VEL/VOX Is Well Tolerated and Results in High SVR12 in Genotype 1-6
HCV-Infected Patients With Minimal Fibrosis: a Retrospective Analysis of the ASTRAL and POLARIS Clinical Studies
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-21 Amsterdam Netherlands
Eric Lawitz,1 Marc Bourlière,2 Lingling Han,3 John McNally,3 Luisa M. Stamm,3 Diana M. Brainard,3 G M. Subramanian,3 Steven L. Flamm,4 K. Rajender Reddy5
1Texas Liver Institute, The University of Texas Health Science Center at San Antonio, USA; 2Hôpital Saint Joseph Marseille, France; 3Gilead Sciences, Inc., Foster City, California, USA; 4Northwestern University, Chicago, Illinois, USA; 5University of Pennsylvania, Philadelphia, USA
AASLD: A Randomized, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study - (11/15/16)
AASLD: A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6 HCV Infected Patients: The POLARIS-2 Study - (11/15/16)
AASLD: Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage Regimen in NS5A Inhibitor-Experienced Patients With Genotype 1-6 Infection: The Phase 3 POLARIS-1 Study - (11/15/16)
References
1. Kowdley KV, et al. N Engl J Med 2014;370:1879-88; 2. Feld JJ, et al. N Engl J Med 2015;373:2599-607; 3. Foster GR, et al. N Engl J Med 2015;373:2608-17; 4. Jacobson IM, et al. Hepatology 2016;64(suppl):1126A; 5. Foster GR, et al. Hepatology 2016;63:135A; 6. BioPredictive: http://www.biopredictive.com/intl/physician/fibrotest-for-hcv.
|
| |
|
|
|
|
|
